Patents Assigned to Taiho Pharmaceutical Co., LTD
  • CANCER THERAPY USING 3,5-DISUBSTITUTED BENZENE ALKYNYL COMPOUND AND MEK INHIBITOR
    Publication number: 20230165862
    Abstract: Provided is a novel combination therapy that exhibits excellent antitumor effects, and that uses an FGFR-inhibiting compound and an MEK inhibitor. An antitumor agent contains (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a salt thereof as an active ingredient and is administered in combination with an MEK inhibitor.
    Type: Application
    Filed: April 9, 2021
    Publication date: June 1, 2023
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi HIRAI, Kazuaki MATSUOKA, Akihiro MIURA
  • ENHANCEMENT OF ANTI-TUMOR ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NOVEL CANCER MEDICINES IN CANCERS
    Publication number: 20230146795
    Abstract: The present invention provides a combination drug for the treatment of a malignant tumor comprising 2-((1R,2R,4S)-2-amino-7-azabicyclo[2.2.1]heptan-7-yl)-5-(3,4-dichloro-2-methyl-2H-indazol-5-yl)-3-methyl-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one or a pharmaceutically acceptable salt thereof, and at least one additional compound having an antitumor effect or at least one pharmaceutically acceptable salt thereof, and a pharmaceutical composition comprising both the active ingredients.
    Type: Application
    Filed: January 22, 2021
    Publication date: May 11, 2023
    Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Takuya HOSHINO, Yu KOMIYA, Yoko NAKATSURU, Nicola Gail WALLIS
  • PROCESS FOR PRODUCING ACYLTHIOUREA COMPOUND
    Publication number: 20230107889
    Abstract: The present invention relates to a process for producing 4-(2-fluoro-4-(3-(2-phenylacetyl)thioureido)phenoxy)-7-methoxy-N-methylquinoline-6-carboxamide, including: coupling 4-(4-amino-2-fluorophenoxy)-7-methoxy-N-methylquinoline-6-carboxamide to 2-phenylacetyl isothiocyanate.
    Type: Application
    Filed: February 12, 2021
    Publication date: April 6, 2023
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Yoshimitsu SUDA
  • TREATMENT FOR CHONDRODYSTROPHIA
    Publication number: 20230097475
    Abstract: A pharmaceutical composition for treating cartilage dysplasia, comprising 1-[(3S)-3-[4-amino-3-[2-(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-pyrrolidinyl]-2-propen-1-one or a pharmaceutically acceptable salt thereof, and a treatment method using the pharmaceutical composition.
    Type: Application
    Filed: January 29, 2021
    Publication date: March 30, 2023
    Applicants: Kyoto University, TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Noriyuki TSUMAKI, Yuki IIMORI, Akihiro MIURA, Hiroshi HIRAI
  • Anti-tumor agent containing immunomodulator, and antitumor effect potentiator
    Patent number: 11612653
    Abstract: Provided is a novel cancer treatment method with less side effects, showing remarkably excellent antitumor effect. An antitumor agent is used for administering a DNA function inhibitor and an immunomodulator in combination.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 28, 2023
    Assignee: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Norihiko Suzuki
  • THERAPEUTIC AGENT CONTAINING FUSED PYRIMIDINE COMPOUND AS ACTIVE INGREDIENT
    Publication number: 20230064254
    Abstract: [Problem] Provided is a novel therapeutic agent for chronic glomerulonephritis.
    Type: Application
    Filed: December 18, 2020
    Publication date: March 2, 2023
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Yasunobu ARIMA, Ryusuke KANEKO
  • AGENT FOR ADJUVANT THERAPY
    Publication number: 20230055953
    Abstract: The present invention provides an agent for adjuvant therapy of tumors that exerts remarkable inhibitory effects on tumor metastasis and recurrence while developing few side effects. The agent for adjuvant therapy comprises, as an active ingredient, a peptide having 4 linked CTL epitopes.
    Type: Application
    Filed: December 25, 2020
    Publication date: February 23, 2023
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventor: Risa Goto
  • PYRAZOLO[3,4-B]PYRAZINE SHP2 PHOSPHATASE INHIBITORS
    Publication number: 20230049719
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Application
    Filed: August 20, 2020
    Publication date: February 16, 2023
    Applicants: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Steven HOWARD, John Walter LIEBESCHUETZ, Tadashi SHIMAMURA
  • Anti-tumor effect potentiator using novel biphenyl compound
    Patent number: 11510915
    Abstract: An antitumor formulation comprising a biphenyl compound having LSD1 inhibitory activity or a salt thereof and one or more other antitumor agents that are administered in combination, the compound being represented by Formula (I): wherein ring A, ring B, R1 to R6, l, m, and n are as defined in the specification.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: November 29, 2022
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventor: Akiko Osada
  • HETEROBICYCLIC COMPOUNDS FOR INHIBITING THE ACTIVITY OF SHP2
    Publication number: 20220363693
    Abstract: A compound of formula (I): wherein Ring A, Q, R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X, a, b, c and d are as defined in the specification.
    Type: Application
    Filed: July 23, 2019
    Publication date: November 17, 2022
    Applicants: TAIHO PHARMACEUTICAL CO., LTD., OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Tadashi SHIMAMURA, Ryo KATO, Risako MIURA, Takashi MITA, Takahiro OGAWA, Yufu SAGARA, Christopher Norbert JOHNSON, Steven HOWARD, James Edward Harvey DAY, Jeffrey David ST. DENIS, John Walter LIEBESCHUETZ
  • METHOD FOR TREATING MALIGNANT TUMOR
    Publication number: 20220354858
    Abstract: A method for treating a malignant tumor of a human patient, the method comprising administering trans-3-amino-1-methyl-3-(4-(3-phenyl-5H-imidazo[1,2-c]pyrido[3,4-e][1,3]oxazin-2-yl)phenyl)cyclobutanol (Compound 1) or a salt thereof to a patient in need of the treatment according to an administration schedule in which the Compound 1 or a salt thereof is administered in a dose of 4 mg/body/day to 160 mg/body/day in tams of Compound 1 for 4 consecutive days, followed by a prescribed withdrawal period of 3 days.
    Type: Application
    Filed: June 19, 2020
    Publication date: November 10, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Kazuo KOBA, Toshiyasu SHIMOMURA
  • Manufacturing method for high-purity cyclohexenone long-chain alcohol
    Patent number: 11485696
    Abstract: This invention relates to a method for producing a high-purity cyclohexenone long-chain alcohol represented by formula I, and produces the compound of formula I by a metal-mediated Barbier reaction. The method of the present invention has advantages in its short scheme, high yield, and high-purity product, and is suitable for industrial scale up.
    Type: Grant
    Filed: January 22, 2017
    Date of Patent: November 1, 2022
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Jian Zhang, Dehui Jiang, Xiaojun Shen
  • Biphenyl compound or salt thereof
    Patent number: 11479563
    Abstract: The present invention provides a compound represented by Formula (I) or a salt thereof; an LSD1 inhibitor that contains the compound or a salt thereof as an active ingredient; a pharmaceutical composition that contains the compound or a salt thereof; and an antitumor agent that contains the compound or a salt thereof as an active ingredient.
    Type: Grant
    Filed: May 25, 2018
    Date of Patent: October 25, 2022
    Assignee: Taiho Pharmaceutical Co., Ltd.
    Inventors: Satoshi Yamashita, Takahiro Ogawa
  • Pharmaceutical compounds
    Patent number: 11466016
    Abstract: The invention provides new pyrazine derivatives of formula (I): or a tautomer or a solvate or a pharmaceutically acceptable salt thereof, wherein the substituents are as defined herein. The invention also provides pharmaceutical compositions comprising said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
    Type: Grant
    Filed: March 1, 2019
    Date of Patent: October 11, 2022
    Assignees: OTSUKA PHARMACEUTICAL CO., LTD., TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Christopher Norbert Johnson, Ildiko Maria Buck, Gianni Chessari, James Edward Harvey Day, Hideto Fujiwara, Christopher Charles Frederick Hamlett, Steven Douglas Hiscock, Rhian Sara Holvey, Steven Howard, John Walter Liebeschuetz, Nicholas John Palmer, Jeffrey David St Denis, David Geoffrey Twigg, Andrew James Woodhead
  • COMBINATION THERAPY FOR CANCER USING AZABICYCLIC COMPOUND AND POLY(ADENOSINE 5'-DIPHOSPHATE-RIBOSE) POLYMERASE INHIBITOR
    Publication number: 20220280489
    Abstract: Provided is a novel method for treating cancer with a high antitumor effect. The present invention provides an antitumor agent comprising an azabicyclo compound of the following Formula (I) or a salt thereof and a poly(adenosine 5?-diphosphate-ribose) polymerase inhibitor which are administered in combination.
    Type: Application
    Filed: August 5, 2020
    Publication date: September 8, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiromi MURAOKA, Naoki ARIMURA
  • NOVEL PHOSPHATE ESTER COMPOUND HAVING PYRROLOPYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20220267365
    Abstract: There is provided a novel phosphate ester compound having a pyrrolopyrimidine skeleton having an excellent antitumor effect or a pharmaceutically acceptable salt thereof, and a method for preventing and/or treating a tumor in combination with an alkylating agent and/or a radiation therapy. According to one aspect of the present invention, there is provided a compound represented by the following general formula (1) or a pharmaceutically acceptable salt thereof, and a method for preventing and/or treating a tumor in combination with an alkylating agent and/or a radiation therapy.
    Type: Application
    Filed: June 17, 2020
    Publication date: August 25, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hitoshi MIYAKOSHI, Nozomu TANAKA, Yu KOBAYAKAWA
  • PHARMACEUTICAL COMPOSITION AND THERAPEUTIC METHOD FOR TREATING FGFR1 VARIANT-POSITIVE BRAIN TUMOR
    Publication number: 20220241280
    Abstract: The present invention provides a pharmaceutical composition for treating a patient with an FGFR1 mutant-positive brain tumor, the composition comprising (S)-1-(3-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)pyrrolidin-1-yl)prop-2-en-1-one or a pharmaceutically acceptable salt thereof as an active ingredient; and a therapeutic method using the pharmaceutical composition.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 4, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hiroshi HIRAI, Akihiro MIURA
  • NOVEL CARBONATE COMPOUND HAVING PYRROLOPYRIMIDINE SKELETON OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20220233566
    Abstract: There is provided a novel carbonate compound of a nucleoside having a pyrrolopyrimidine skeleton having an excellent antitumor effect, or a pharmaceutically acceptable salt thereof and a method for preventing and/or treating a tumor in combination with an alkylating agent and/or a radiation therapy. According to one aspect of the present invention, there is provided a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof, and a method for preventing and/or treating a tumor in combination with an alkylating agent and/or a radiation therapy.
    Type: Application
    Filed: June 17, 2020
    Publication date: July 28, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Hitoshi MIYAKOSHI, Nozomu TANAKA, Yu KOBAYAKAWA
  • Combination Treatment of Cancer Using Sulfonamide Compound and Immune Regulator
    Publication number: 20220226291
    Abstract: This invention provides a method for enhancing antitumor effects of a ribonucleotide reductase (RNR) inhibitory compound. A pharmaceutical composition for treating and/or preventing a tumor used in combination with an immune checkpoint molecule regulator comprising a sulfonamide compound represented by Formula (I) or a salt thereof is also provided.
    Type: Application
    Filed: May 28, 2020
    Publication date: July 21, 2022
    Applicant: Taiho Pharmaceutical Co., Ltd.
    Inventors: Hiroyuki Ueno, Sayaka Tsukioka
  • ORAL PHARMACEUTICAL COMPOSITION
    Publication number: 20220218602
    Abstract: The present invention provides an FTD and TPI-containing oral pharmaceutical composition which can be orally administered and is stable even under high humidity conditions. An oral pharmaceutical composition comprising ?,?,?-trifluorothymidine and 5-chloro-6-(2-iminopyrrolidine-1-yl)methyl-2,4(1H,3H)-pyrimidine dione hydrochloride as an active ingredient; and being substantially free of an additive comprising a metal salt.
    Type: Application
    Filed: April 4, 2022
    Publication date: July 14, 2022
    Applicant: TAIHO PHARMACEUTICAL CO., LTD.
    Inventors: Yoshito OHNISHI, Tetsuo OGATA